首页> 美国卫生研究院文献>Neoplasia (New York N.Y.) >A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
【2h】

A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer

机译:TGF-β/ c-KIT阳性反馈环驱动晚期原发性肝癌的肿瘤进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor suppressor to tumor promoter in HCC and its interactions with other signaling pathways are poorly understood. Here, we demonstrate an aberrant molecular network between the TGF-β and c-KIT pathway that mediates the functional switch of TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT receptor ligand (stem cell factor [SCF]) with subsequent auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. SCF induces TGF-β1 ligand expression via STAT3, thereby forming a positive feedback loop between TGF-β/SMAD and SCF/c-KIT signaling. This network neutralizes TGF-β–mediated cell cycle inhibition and induces tumor cell proliferation, epithelial-to-mesenchymal-transition, migration, and invasion. Disruption of this feedback loop inhibits TGF-β tumor-promoting effects and restores its antiproliferative functions. Consistent with our in vitro data, we demonstrate SCF overexpression and its correlation to SMAD2 and STAT3 activation in human HCC tumors, advanced tumor-node-metastasis stages, and shorter survival. CONCLUSIONS: Canonical TGF-β and c-KIT signaling forms a positive, tumor-promoting feedback loop. Disruption of this loop restores TGF-β tumor suppressor function and provides the rationale for targeting the TGF-β/SCF axis as a novel therapeutic strategy for HCC.
机译:肝细胞癌(HCC)是全球第二大最常见的癌症死亡原因。大多数HCC患者被诊断为晚期疾病,尚无治疗方法。 TGF-β已被确定为潜在的治疗靶标。然而,人们尚不了解介导其在肝癌中从肿瘤抑制物向肿瘤启动子转变的分子机制及其与其他信号通路的相互作用。在这里,我们证明了TGF-β和c-KIT通路之间的异常分子网络介导了TGF-β的功能转换为HCC中肿瘤进展的驱动器。 TGF-β/ SMAD2信号转导可调控c-KIT受体配体(干细胞因子[SCF])的表达,并随后激活c-KIT / JAK1 / STAT3信号的自分泌和旁分泌激活。 SCF通过STAT3诱导TGF-β1配体表达,从而在TGF-β/ SMAD和SCF / c-KIT信号传导之间形成正反馈回路。该网络中和了TGF-β介导的细胞周期抑制作用,并诱导肿瘤细胞增殖,上皮到间质转化,迁移和侵袭。该反馈回路的破坏抑制了TGF-β的肿瘤促进作用,并恢复了其抗增殖功能。与我们的体外数据一致,我们证明了SCF过表达及其与人HCC肿瘤中SMAD2和STAT3激活的相关性,晚期肿瘤淋巴结转移阶段和较短的生存期。结论:典型的TGF-β和c-KIT信号传导形成了一个积极的,促进肿瘤的反馈回路。破坏该环可恢复TGF-β肿瘤抑制功能,并提供靶向TGF-β/ SCF轴的理由,作为治疗HCC的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号